New pill BTM-3566 takes on tough lymphoma in early trial
NCT ID NCT06792734
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial is testing an oral drug called BTM-3566 in 24 adults with relapsed or refractory B-cell lymphoma. The main goals are to find a safe dose and see if the drug can slow or stop the cancer. Participants take the drug for 7 days, then have 7 days off, and visit the clinic regularly for checkups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BTM-3566 (an oral drug)
What this could lead to
If it works, this could point toward a new treatment option for people with B-cell lymphoma that has not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 24 participants, so the main goal is safety, not effectiveness. The drug may cause side effects or not work well enough to move forward.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, B-CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
Contact